drugset / Trial / NCT02460900
Optimizing Smoking Cessation for People With HIV/AIDS Who Smoke
Phase 3
Completed
184 enrolled
University of Maryland, Baltimore
National Heart, Lung, and Blood Institute (NHLBI) · collab
RandomizedFactorialQuadruple-blindTreatment
Summary
The single greatest health behavior change that could improve cardiovascular morbidity and associated mortality is to assist people living with HIV/AIDS who smoke to quit. The investigators will use a factorial design to evaluate the most promising behavioral and pharmacologic treatments aimed at achieving maximal efficacy for smoking cessation among people living with HIV/AIDS who smoke. Results of this study will provide crucial, real world evidence of the best way for healthcare providers to help smokers living with HIV/AIDS quit smoking.
Timeline
- Start
- 2016-07
- Primary completion
- 2021-04
- Completion
- 2021-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Varenicline | Small molecule | — | — |